Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

NCT02485600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2021-06-25

No results posted yet for this study

Summary

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

Conditions

  • Parkinson Disease (PD)

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-19
Primary Completion
2020-02-26
Completion
2020-02-26

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485600 on ClinicalTrials.gov